Cardiac transplantation and circulatory support devices

Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease: Fourth Edition

Volumn , Issue , 2012, Pages 307-321

  Teuteberg, Jeffrey ^a   Mathier, Michael A ^a   Shullo, Michael A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903097880     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0101-8.00015-1     Document Type: Chapter

References (144)

1. OPTN/SRTR Annual Report 2010 Available at, Accessed September. http://www.srtr.org/annual_reports/2010/.
2. Stehlik J, Edwards LB, Kucheryavaya AY, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report-2010. J Heart Lung Transplant 2010, 29:1089-1101.
3. Cimato TR, Jessup M Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J Heart Lung Transplant 2002, 21:1161-1173.
4. Mancini D, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 82:778-786.
5. Pohwani AL, Murali S, Mathier MA, et al. Impact of beta-blocker therapy on functional capacity criteria for heart transplant listing. J Heart Lung Transplant 2003, 22:78-86.
6. Gitt AK, Wasserman K, Kilkowski C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation 2002, 106:3079-3084.
7. Cahalin LP, Mathier MA, Semigran MJ, et al. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996, 110:325-332.
8. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
9. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2660-2667.
10. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
11. Costard-Jackle A, Fowler MB Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992, 19:48-54.
12. Kadner A, Chen RH, Adams DH Heterotopic heart transplantation: experimental development and clinical experience. Eur J Cardiothorac Surg 2000, 17:474-481.
13. Baran DA, Galin ID, Courtney MC, et al. Cardiac transplantation in the older recipient: Excellent long-term survival based on pretransplant screening. Transplant Proc 2003, 35:2465-2467.
14. Blanche C, Blanche DA, Kearney B, et al. Heart transplantation in patients seventy years of age and older: a comparative analysis of outcome. J Thorac Cardiovasc Surg 2001, 121:532-541.
15. Murali S, Tokarczyk T, Ristich J, et al. Short-term survival with combined heart-kidney or combined heart-liver transplantation with allografts from a single donor. J Heart Lung Transplant 2001, 20:168.
16. Blanche C, Kamlot A, Blanche DA, et al. Combined heart-kidney transplantation with single-donor allografts. J Thorac Cardiovasc Surg 2001, 122:495-500.
17. Morgan JA, John R, Weinberg AD, et al. Heart transplantation in diabetic recipients: a decade review of 161 patients at Columbia Presbyterian. J Thorac Cardiovasc Surg 2004, 127:1486-1492.
18. Costanzo, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010, 29:914-956.
19. Laks H, Marelli D, Fonarow GC, et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg 2003, 125:49-59. UCLA Heart Tranplant Group.
20. Chen JM, Russo MJ, Hammond KM, et al. Alternate waiting list strategies for heart transplantation maximize donor organ utilization. Ann Thorac Surg 2005, 80:224-228.
21. Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation: a preliminary study. Eur J Cardiothorac Surg 2004, 25:971-977.
22. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999, 18:701-706.
23. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999, 100(19 Suppl):II229-II235.
24. Beniaminovitz A, Savoia MT, Oz M, et al. Improved atrial function in bicaval versus standard orthotopic techniques in cardiac transplantation. Am J Cardiol 1997, 80:1631-1635.
25. Brandt M, Harringer W, Hirt SW, et al. Influence of bicaval anastomoses on late occurrence of atrial arrhythmia after heart transplantation. Ann Thorac Surg 1997, 64:70-72.
26. Morgan JA, Edwards NM Orthotopic cardiac transplantation: comparison of outcome using biatrial, bicaval, and total techniques. J Card Surg 2005, 20:102-106.
27. Faggian G, Forni A, Mazzucco A Donor organ preservation in high-risk cardiac transplantation. Transplant Proc 2004, 36:617-619.
28. Morgan JA, John R, Weinberg AD, et al. Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg 2003, 126:1624-1633.
29. Stobierska-Dzierzek B, Awad H, Michler RE The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001, 38:923-931.
30. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001, 72:638-641.
31. Kavarana MN, Sinha P, Naka Y, et al. Mechanical support for the failing cardiac allograft: A single-center experience. J Heart Lung Transplant 2003, 22:542-547.
32. Halloran PF Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351:2715-2729.
33. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005, 24:1710-1720.
34. Pham MX, Teuteberg JT, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010, 362:1890-1900.
35. Fishman JA Infection in solid-organ transplant recipients. New Engl J Med 2007, 357:2601-2614.
36. Brann WM, Bennett LE, Keck BM, et al. Morbidity, functional status, and immunosuppressive therapy after heart transplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant 1998, 17:374-382.
37. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
38. Teuteberg JJ, Shullo M Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant 2008, 22:730-737.
39. Baran DA, Zucker MJ, Arroyo LH, et al. Randomized trial of tacrolimus monotherapy: Tacrolimus In Combination, Tacrolimus Alone Compared (the TICTAC Trial). J Heart Lung Transplant 2007, 26:992-997.
40. Teuteberg JJ, Shullo MA, Zomak R, et al. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant 2008, 22:730-737.
41. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplantation 2010, 10:382-388.
42. Schonder K, Shullo MA, Okusanya O Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003, 37:1793-1796.
43. Rubin RH Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000, 19:731-735.
44. Keay S Cardiac transplantation: Pre-transplant infectious diseases evaluation and post-transplant prophylaxis. Curr Infect Dis Rep 2002, 4:285-292.
45. Haddad F, Deuse T, Pham M, et al. Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant 2010, 29:306-315.
46. Eisen HJ Hypertension in heart transplant recipients: more than just cyclosporine. J Am Coll Cardiol 2003, 41:433-434.
47. Brozena SC, Johnson MR, Ventura H, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. J Am Coll Cardiol 1996, 27:1707-1712.
48. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993, 328:164-170.
49. Lang CC, Beniaminovitz A, Edwards N, et al. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 2003, 22:244-249.
50. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002, 73:775-778.
51. Teuteberg JJ, Shullo MA Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010, 10:382-388.
52. Marchetti P New-onset diabetes after transplantation. J Heart Lung Transplant 2004, 23:S194-S201.
53. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 2003, 75:SS3-SS24.
54. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999, 18:336-345.
55. Fatemeh A, Jackson CH, Parameshwar J, et al. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2003, 73:1258-1264.
56. Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995, 14:613-622.
57. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation. Circulation 2003, 107:93-97.
58. Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation. J Heart Lung Transplant 2000, 19:529-537.
59. Bonet LA, Martinez-Dolz L, Vives MA, et al. Lipid-lowering effect of atorvastatin in heart transplantation. Transplantation Proc 2002, 34:179-181.
60. Jimenez J, Kapadia SR, Yamani MH, et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant 2001, 20:393-398.
61. Valantine H Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004, 23:S187-S193.
62. Subramanian AK, Quinn TC, Kickler TS, et al. Correlation of Chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002, 73:761-764.
63. Schwaiblmair M, von Scheidt W, Uberfuhr P, et al. Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy. Chest 1999, 116:332-339.
64. Aranda JM, Pauly DF, Kerensky RA, et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. J Heart Lung Transplant 2002, 21:860-866.
65. Schnetzler B, Drobinski G, Dorent R, et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000, 19:557-565.
66. Lee MS, Tarantini G, Xhaxho J, et al. Sirolimus- versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy. J Am Coll Cardiol Int 2010, 3:378-382.
67. Weis M, Pehlivanli S, Meiser BM, et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001, 38:814-818.
68. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005, 24:1736-1740.
69. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847-858.
70. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.
71. Doshi AA, Rogers J, Kern MJ, et al. Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. Am J Cardiol 2004, 93:90-92.
72. Ono M, Michler RE Beating heart coronary artery bypass surgery after orthotopic heart transplantation. J Card Surg 2003, 18:545-549.
73. Aleksic I, Piotrowski JA, Kamler M, et al. Minimally invasive direct coronary artery bypass in a cardiac transplant recipient with allograft vasculpathy. Ann Thorac Surg 2004, 77:1433-1434.
74. Radovancevic B, McGiffin DC, Kobashigawa JA, et al. Reptransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J Heart Lung Transplant 2003, 22:862-868.
75. Topkara VK, Dang NC, John R, et al. A decade experience of cardiac retransplantation in adult recipients. J Heart Lung Transplant 2005, 24:1745-1750.
76. Sehgal V, Radhakrishnan J, Appel GB, et al. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids and hypertension. Am J Kidney Dis 1995, 26:193-201.
77. Vossler MR, Ni H, Toy W, et al. Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation. J Heart Lung Transplant 2002, 21:874-881.
78. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004, 77:568-574.
79. Engelen MA, Almer S, et al. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years. Transplantation 2011, 91:1159-1165.
80. Frimat L, Villemot JP, Cormier L, et al. Treatment of end-stage renal failure after heart transplantation. Nephrol Dial Transplant 1998, 13:2905-2908.
81. Gutierrez-Dalmau A, Campistol JM Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67(8):1167-1198.
82. Domhan S, Zeier M, Abdollahi A Immunosuppressive therapy and posttransplant malignancy. Nephrol Dial Transplant 2009, 24:1097-1103.
83. Kiberd BA, Rose C, Gill JS Cancer mortality in kidney transplantation. Am J Transplantation 2009, 9:1868-1875.
84. Vajdic CM, van Leeuwen MT Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009, 125:1747-1754.
85. Jemec GBE, Holm EA Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003, 75:253-257.
86. Fortina AB, Caforio AL, Piaserico S, et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000, 19:249-255.
87. Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003, 22:505-514.
88. Demers P, Moffatt S, Oyer PE, et al. Long-term results of heart transplantation in patients older than 60 years. J Thorac Cardiovasc Surg 2003, 126:224-231.
89. DiNardo CD, Tsai DE Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol 2010, 17:368-374.
90. Chen K, Craig JC, Shumack S Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005, 152:518-523.
91. Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation 2008, 118:S94-S105.
92. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873-1884.
93. Latif N, Yacoub MH, George R, Barton PJ, Birks EJ Changes in sarcomeric and non-sarcomeric cytoskeletal proteins and focal adhesion molecules during clinical myocardial recovery after left ventricular assist device support. J Heart Lung Transplant 2007, 26:230-235.
94. Rodrigue-Way A, Burkhoff D, Geesaman BJ, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant 2005, 24:73-80.
95. Bruggink AH, van Oosterhout MF, de Jonge N, et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006, 25:1091-1098.
96. Ogletree-Hughes ML, Stull LB, Sweet WE, et al. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 2001, 104:881-886.
97. Bruckner BA, Stetson SJ, Perez-Verdia A, et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001, 20:457-464.
98. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001, 344:1750-1757.
99. Allen JG, Weiss ES, Schaffer JM, et al. Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation. J Heart Lung Transplant 2010, 29:278-285.
100. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
101. Slaughter MS, Rogers JG, Milano CA, et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009, 361:2241-2251.
102. Stevenson LW, Rose EA Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom?. Circulation 2003, 108:3059-3063.
103. Morris RJ Total artificial heart: concepts and clinical use. Semin Thorac Cardiovasc Surg 2008, 20:247-254.
104. Fukamachi K, McCarthy PM, Smedira NG, et al. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg 1999, 68:2181-2184.
105. Bhama JK, Kormos RL, Toyoda Y, et al. Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J Heart Lung Transplant 2009, 28:971-976.
106. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002, 106:I198-I202.
107. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg 2002, 73:745-750.
108. Tsukui H, Teuteberg JJ, Murali S, et al. Biventricular assist device utilization for patients with morbid congestive heart failure: a justifiable strategy. Circulation 2005, 112-165.
109. Fitzpatrick JR, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg 2009, 137:971-977.
110. Zahr F, Ootaki Y, Starling RC, et al. Preoperative risk factors for mortality after biventricular assist device implantation. J Card Fail 2008, 14:844-849.
111. Okuda M A multidisciplinary overview of cardiogenic shock. Shock 2006, 25:557-570.
112. Kirklin JK, Naftel DC, Stevenson LW, et al. INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant 2008, 27:1065-1072.
113. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007, 50:741-747.
114. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008, 27:943-956.
115. Wilson SR, Mudge GH, Stewart GC, Givertz MM Evaluating for ventricular assist device: selecting the appropriate candidate. Circulation 2009, 119:2225-2232.
116. Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011, 57:1375-1382.
117. Starling RA, Naka Y, Boyle AJ, et al. Results of the post-US Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to transplantation: A prospective study using INTERMACS. J Am Coll Cardiol 2011, 57:1890-1898.
118. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?. J Heart Lung Transplant 2009, 28:231-236.
119. Deng MC, Loebe M, El-Banayosy A, et al. Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome. Circulation 2001, 103:231-237.
120. Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation 1995, 92-II169.
121. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007, 116:497-505.
122. Teuteberg JJ, Ewald G, Adamson R, et al. Application of the destination therapy risk score to HeartMateII clinical trial data. J Heart Lung Transplant 2011, 30:S31.
123. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
124. Ketchum ES, Moorman AJ, Fishbein DP, et al. Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement. J Heart Lung Transplant 2010, 29:1021-1025.
125. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009, 28:535-541.
126. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009, 54:312-321.
127. Boyle AJ, Teuteberg JJ, Ascheim DD, et al. LVADs for less acutely ill patients: Do current data justify the strategy?. ASAIO 2008, 54:A22.
128. Mandarino WA, Winowich S, Gorcsan J, et al. Right ventricular performance and left ventricular assist device filling. Ann Thorac Surg 1997, 63:1044-1049.
129. Matthews JC, Koelling TM, Pagani FD, Aaronson KD The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008, 51:2163-7212.
130. Wilson SR, Mudge GH, Stewart GC, Givertz MM Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 2009, 119:2225-2232.
131. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular function in patients with the HeartMateII continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes. J Thoracic Cardiovasc Surg 2010, 139:1316-1324.
132. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 2009, 28:44-50.
133. Schulman AR, Martens TP, Russo MJ, et al. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant 2009, 28:237-242.
134. Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009, 87:1072-1078.
135. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 2006, 81:1745-1751.
136. Topkara VK, Dang NC, Barili F, et al. Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. J Heart Lung Transplant 2006, 25:404-408.
137. Mano A, Fujita K, Uenomachi K, et al. Body mass index is a useful predictor of prognosis after left ventricular assist system implantation. J Heart Lung Transplant 2009, 28:428-433.
138. Butler J, Howser R, Portner PM, Pierson RN Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg 2005, 79:66-73.
139. Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 2011, 92:1420-1427.
140. Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired vonWillebrand factor-dependent platelet aggregation in patients with a continuous flow left ventricular assist device (HeartMateII). J Am Coll Cardiol 2009, 53:2162-2167.
141. Demirozu ZT, Radovancevic R, Hochman LF, et al. Ateriovenous malformations and gastrointestinal bleeding in patients with the HeartMateII left ventricular assist device. J Heart Lung Transplant 2011, 30:849-853.
142. Mehra MR, Uber PA, Uber WE, Scott RL, Park MH Allosensitization in heart transplantation: implications and management strategies. Curr Opin Cardiol 2003, 18:153-158.
143. Holman WL, Park SJ, Long JW, et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 2004, 23:1359-1365.
144. Pak SW, Uriel N, Takayama H, et al. Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant 2010, 29:1172-1176.